Chicharros USA - bolsa internacional

Como trabajo de mañanas y siempre llego tarde a ver las pre, no tengo claro a qué hora abren, creo que a las 12:00 del mediodia hora de aquí ¿no?

Las Pre, Eleuterio, si no me equivoco, creo que comienzan una hora y media antes de la apertura.. es decir, a las 14:00h

en realidad, premarket abre 5,5h antes de apertura
y el after hour esta abierto hasta pasadas 2,5h tras el cierre de sesion

How are the Nasdaq-100 Pre-Market and After Hours Indicators calculated? The Indicators are minute by minute calculations during extended hours trading, using the same calculation used for the Nasdaq-100 Index during regular market hours.

The Pre-Market Indicator is calculated based on last sale prices of Nasdaq-100 securities during pre-market trading, 4:00 to 9:30 a.m. ET. If a Nasdaq-100 security does not trade during the pre-market, the calculation uses last sale from the previous day 4 p.m. closing price.

The After Hours Indicator is calculated based on last sale prices of Nasdaq-100 securities during after hours trading, 4:00 to 6:30 p.m. ET. And if a Nasdaq-100 security does not trade in the after hours market, the calculation uses last sale price from that day's 4 p.m. closing. Read more: http://www.nasdaq.com/extended-trading/#ixzz3mz6hAja4

Esta muy bien tener valores seguros, llevo 2000 acciones de Starbuxs,que ahora están en 58$ los compre en ese mismo precio días antes de ese recorte tan bestial, llego a 44$, la verdad es que me desanime bastante,llegando incluso a largar las Nvax en un ataque de pánico sobre los 10,50$ ,ahora me alegro después de ver dónde está, en definitiva lo que quiero decir es que para dar un buen pelotazo ahí que mirar chicharros de este tipo, y llegado el caso poner bastante carne en el asador., a riesgo de batacazo, pero es lo que hay.
Si de verdad AEZS demuestra aptitudes, no dudaré en meterle mas pasta.

Mucha suerte y quien la sigue la consigue........

News GALE....
+16% en pre....
A ver s peta los 2.39 y tenemos un buen subidón....

http://www.streetinsider.com/Corporate+News/Galena+Biopharma+%28GALE%29+Announces+Presentation+of+GALE-301+Phase+2a+Data+at+ERS+Congress/10923059.html?si_client=intbro

GALE

ARRY, news...

Array will hold a conference call to discuss these results and preliminary results from a colorectal cancer trial on Monday, September 28, 2015. Ron Squarer, Chief Executive Officer, and Victor Sandor, M.D., Chief Medical Officer, will lead the call.

Conference Call Information
Date:
Monday, September 28, 2015
Time:
9:00 a.m. eastern time
Toll-Free:
(844) 464-3927
Toll:
(765) 507-2598
Pass Code:
43837177
Webcast, including Replay and Conference Call Slides: http://edge.media-server.com/m/p/ky8z35w4/lan/en
BRAF-mutant Melanoma Preliminary Results

LOGIC2 is an ongoing 140-patient, two-part study designed to explore the safety and activity of novel triplet combinations in BRAF-mutant melanoma. In part 1, patients are treated with the combination of binimetinib and encorafenib until disease progression. Based on the results of molecular profiling at that time, each patient is assigned to one of four arms containing a triplet combination of binimetinib, encorafenib and a third targeted therapy. Results from part 1 of the study are reported separately for patients who have previously received a BRAF and/or MEK inhibitor versus those who were initially naive to BRAF and MEK inhibitor treatment.

In part 1, patients are treated with binimetinib 45 mg twice daily (BID) and encorafenib 450 mg once daily (QD), the same doses evaluated in the ongoing Phase 3 COLUMBUS trial. In the BRAF/MEK-naive group (n=40), the interim overall response rate (confirmed and unconfirmed complete response or partial response) was 68%, with a 6-month progression-free survival estimate of 79%. Of note, 96% of patients in this group continued to receive study treatment as of the data cutoff. Preliminary data from all patients in the study (n=89) also indicate that the combination of binimetinib and encorafenib showed good tolerability with a 12% incidence of pyrexia and little to no rash or photosensitivity. These results indicate that the combination of binimetinib and encorafenib show encouraging clinical activity and an emerging differentiated tolerability profile relative to other MEK/BRAF inhibitor combinations.

"MEK and BRAF combination therapy is now established as the optimal molecularly targeted approach for BRAF mutant melanoma patients," said Reinhard Dummer, M.D., investigator, University Hospital Zurich. "In this study, the combination of encorafenib and binimetinib demonstrated robust clinical activity, consistent with results from other BRAF/MEK inhibitor combinations, but with a potentially improved and differentiated safety profile."

NRAS-mutant Melanoma Interim Results

A Phase 1b/2 study of binimetinib in combination with ribociclib showed promising preliminary antitumor activity in NRAS-mutant melanoma patients. Results were shared from 45 patients enrolled in the dose escalation portion of the study, which included two dosing schedules (28-day or 21-day cycles). For the 28-day dosing schedule, patients received continuous twice daily dosing of binimetinib while receiving ribociclib for 21 days per 28 day cycle. For the 21-day schedule, both agents were delivered for 14 days of a 21 day cycle.

For patients receiving the combination on a 28-day cycle (n=22), the Objective Response Rate (ORR, confirmed and unconfirmed complete or partial responses) was 41%, the Disease Control Rate (DCR, confirmed and unconfirmed complete or partial responses and stable disease) was 82% with a median Progression Free Survival (mPFS) of 6.7 months. Furthermore, the ORR was 56% (n=9) for patients receiving dose level 1 of the 28-day schedule consisting of binimetinib 45 mg BID and the lowest dose of ribociclib (200 mg QD), indicating that robust activity can be achieved with this dose and schedule. Common treatment-related adverse events included elevated creatine phosphokinase (CPK), skin and gastrointestinal events. Investigation of an alternative 21-day schedule is ongoing.

"Among metastatic melanoma patients, the presence of an NRAS-mutation is a predictor of poor prognosis, and for this subgroup of patients, there are currently no approved targeted therapies," said Carla van Herpen, M.D., Ph.D., Radboud University Medical Center, Nijmegen, The Netherlands. "Simultaneous inhibition of MEK and CDK4/6 protein kinases could suppress the activation of two major signaling pathways associated with NRAS mutations and may provide additive, or synergistic, activity versus single-agent therapy."

- See more at: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=RssLanding&cat=news&id=2090805#sthash.Qlf92r1c.dpuf

ARRY

BT a todos, ya ando por aquí.

AEZS

Sin PM, al menos yo no veo ná en la página del Nasdaq

14% arriba AEZS
http://www.nasdaq.com/es/symbol/aezs/premarket